Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-PTC-01 in Advanced or Metastatic Melanoma
NCT04625205Phase 1Terminated
- Sponsor
- BioNTech SE
- Start
- Dec 2020
- Primary completion
- Mar 2025
- Modality
- Native Immune Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of BNT221 in melanoma (5 arms), sponsored by BioNTech SE. Primary endpoint: Rate of adverse events. Started Dec 2020; status: terminated.
02
Drugs
BNT221
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04625205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625205.